Fig. 5
IL-33 neutralization restrained AIHA development. a–c Female B6 mice (n = 30) were injected with neutralizing antibody to IL-33 or the isotype control, and immunized with rat RBCs for 10 weeks. Then the level of anti-RBC IgG antibody, frequency of circulating reticulocytes and the clearance kinetics of transfused syngeneic mouse RBCs were determined. Each dot represented the results from one mouse. Each bar represented the collective data from control mice (n = 7), IL-33 treated AIHA mice (n = 5) and Ab Ctrl group (n = 11). d The level of anti-RBC IgG antibody in AIHA mice co-injected of IL-33 neutralizing antibody (n = 5) or isotype control (n = 13). Each dot represented the results from one AIHA mouse. e–g Female B6 mice (n = 30) were immunized with rat RBCs plus IL-33 for 10 weeks, and detected for the level of anti-RBC IgG antibody, frequency of circulating reticulocytes and the clearance kinetics of transfused syngeneic mouse RBCs. Each dot represented the results from one mouse. Each bar represented the collective data from five mice. h Serum level of IgG anti-RBC antibody in AIHA mice with (n = 19) or without (n = 12) recombinant IL-33 injection. Each bar represented the collective data (mean ± SD) from each group